Treatment of diabetes mellitus in cardiac patients
Authors:
M. Kvapil
Published in:
Kardiol Rev Int Med 2006, 8(3): 99-104
Category:
Editorial
Overview
The ischaemic heart disease (IHD) mortality rate is high among diabetic patients. Diabetes mellitus is an IHD risk factor in itself. The presence of additional risk factors (dyslipidaemia, pro-coagulation state, insulin resistance, hypertension, hyperuricaemia) is typical of type II diabetes. Conducting diabetic treatment in patients with cardiac disorders is a complex task. It usually involves cooperation with a cardiologist and a diabetologist, specific and strictly dedicated treatment objectives and full use of new therapeutic options.
Keywords:
ischaemic heart disease – diabetes mellitus – treatment of diabetes in cardiac patients
Sources
1.Domandy JA et al. Secondary prevention of macrovascular events in patiens with type 2 diabetes in the PROactive Study:a randomized trial. Lancet 2005; 366: 1279–1289.
2.DCCT/EDIC Study group. Intensive diabetes treatment and cardiovascular disease in patients with typě 1 diabetes. N Eng J Med 2005; 353: 2643-2653.
3.Haffner SM, Lehto S, Rönnemaa T, Pyorälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without previous myocardial infarction implications treatment of hyperlipidemia in diabetic subjects without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
4.Kvapil M. Současné možnosti kombinované farmakologické léčby hypercholesterolemie. DMEV 2005; 8(2): 99–104.
5.Kvapil M. Doba post-statinová. Současné trendy ve snižování rizika kardiovaskulárních komplikací cestou farmakologické intervence sérových lipidů u pacientů s diabetes mellitus 2. typu. In: Perušičová J (eds). Diabetologie 2006. Praha: Triton 2005: 59–79.
6.MRC/BHF. High Protection Study of cholesterol lowering with simvastation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
7.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or inzulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2006 Issue 3
Most read in this issue
- Non-invasive examination in arterial hypertension
- Losartan – more than blood pressure decrease
- Remote monitoring of implantable pacemakers and cardioverters-defibrillators
- Treatment of diabetes mellitus in cardiac patients